Meridian Bioscience Inc. (VIVO: Quote) Monday said it received U.S. FDA clearance for a new molecular diagnostic test for Group A Streptococcus on the illumigene platform.
Group A Streptococcus is a bacteria commonly found in the human throat or on skin and causes a diseases in humans such as acute pharyngitis or strep throat.
The company said illumigene Group A Strep represents a significant new advancement in healthcare by providing a molecular solution for the detection of Group A Strep pharyngitis.
Click here to receive FREE breaking news email alerts for Meridian Bioscience Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org